tradingkey.logo

Medpace Holdings Inc

MEDP
View Detailed Chart
584.570USD
+4.040+0.70%
Close 10/29, 16:00ETQuotes delayed by 15 min
16.43BMarket Cap
37.93P/E TTM

Medpace Holdings Inc

584.570
+4.040+0.70%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.70%

5 Days

+6.92%

1 Month

+16.74%

6 Months

+90.82%

Year to Date

+75.95%

1 Year

+77.27%

View Detailed Chart

TradingKey Stock Score of Medpace Holdings Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Medpace Holdings Inc's Score

Industry at a Glance

Industry Ranking
42 / 407
Overall Ranking
130 / 4623
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 12 analysts
Hold
Current Rating
516.928
Target Price
-10.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Medpace Holdings Inc Highlights

StrengthsRisks
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 44.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.11B.
Overvalued
The company’s latest PE is 39.86, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.67M shares, decreasing 4.49% quarter-over-quarter.
Held by Wasatch Global Investors
Star Investor Wasatch Global Investors holds 945.81K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.05.

Financial Indicators

EPS

No Data

Total revenue

No Data

Medpace Holdings Inc Info

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Ticker SymbolMEDP
CompanyMedpace Holdings Inc
CEODr. August J. Troendle, M.D.
Websitehttps://investor.medpace.com/
KeyAI